Back

Tempus AI agrees to buy Personalis for $1.5 billion as cancer-vaccine boom builds

Verifying
  • Tempus AI agreed to acquire Personalis for $16.25 per share.
  • The transaction values Personalis at $1.5 billion net of Tempus’s existing stake.
  • Personalis participates in tumor sequencing for Moderna’s clinical program.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.